Article - BioPharm International

ADVERTISEMENT

Article

The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines

August 2, 2007

In animal studies, we have demonstrated that the dose of an injected H5N1 vaccine candidate can be significantly reduced by using a skin patch containing E. coli heat-labile enterotoxin (LT) applied over the injection site. LT-activated epidermal Langerhans cells migrate to the nearby draining lymph node and enhance the immune response to the injected antigen. A dry patch formulation has been optimized as a dose sparing strategy for pandemic flu and other vaccines. Iomai Corporation has developed a proprietary stabilizing formulation for the patch that allows use and storage at ambient temperature. The patch withstands temperature extremes during shipment, and is suitable for stockpiling.

Pandemic Flu Preparedness: A Manufacturing Perspective

August 2, 2007

For pandemic vaccine processing, single-use filter cartridges and membrane chromatography technologies could offer significant time- and cost-reduction advantages.

New-Age Vaccine Adjuvants: Friend or Foe?

August 2, 2007

Adjuvant-caused vaccine reactions are one of the most important barriers to better acceptance of routine prophylactic vaccination.

Manufacturing Vaccines in Adherent Cell Lines Using Disposable Multi-tray Bioreactors

August 2, 2007

The recent growth in the vaccine market has led to renewed interest in using adherent human cell lines for vaccine production. Traditionally, small-scale adherent cell line production has been carried out in roller bottles or T-flasks. Over the past few years, however, a number of companies have found multi-tray disposable bioreactors an effective method for producing high-quality drug products using adherent cells. These disposable, expandable systems have also facilitated scale up from laboratory to clinical-scale.

Plasmid DNA–Based Vaccines: Combating Infectious Diseases

August 2, 2007

Like the egg-based vaccine production process, producing a vaccine under cGMP conditions using mammalian cells can be a lengthy process, taking a minimum of six to 12 months.

Vaccine Characterization Using Advanced Technology

August 2, 2007

With the advent of high-resolution mass spectrometers and highly sensitive MS instruments, vaccine characterization has entered a new phase.

From the Editor: After Zheng

August 1, 2007

The corruption of China's food and drug sectors is not limited to one man. Likewise, real reform will require the efforts of many.

Street Talk: Small-Cap Biopharmaceutical Stocks

August 1, 2007

When you start out, keep your small-cap exposure to no more than 10% of your holdings, and gradually increase.

Patents: Patent Strategies for Biotechnology Enterprises

August 1, 2007

Companies in the biotech industry typically require one or several partners as they complete the product development cycle.

ADVERTISEMENT

ADVERTISEMENT

Click here